Humacyte HUMA Stock
Humacyte Price Chart
Humacyte HUMA Financial and Trading Overview
| Humacyte stock price | 1.35 USD |
| Previous Close | 3.45 USD |
| Open | 3.46 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 1200 |
| Day's Range | 3.06 - 3.57 USD |
| 52 Week Range | 1.96 - 5.6 USD |
| Volume | 1.44M USD |
| Avg. Volume | 318.89K USD |
| Market Cap | 346.42M USD |
| Beta (5Y Monthly) | 1.216958 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.26 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.35 USD |
HUMA Valuation Measures
| Enterprise Value | 274.81M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.806818 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 260.07266 |
| Price/Book (mrq) | 4.229798 |
| Enterprise Value/Revenue | 206.314 |
| Enterprise Value/EBITDA | -3.565 |
Trading Information
Humacyte Stock Price History
| Beta (5Y Monthly) | 1.216958 |
| 52-Week Change | -10.66% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.6 USD |
| 52 Week Low | 1.96 USD |
| 50-Day Moving Average | 3.75 USD |
| 200-Day Moving Average | 3.26 USD |
HUMA Share Statistics
| Avg. Volume (3 month) | 318.89K USD |
| Avg. Daily Volume (10-Days) | 619.27K USD |
| Shares Outstanding | 103.41M |
| Float | 56.87M |
| Short Ratio | 10.76 |
| % Held by Insiders | 48.14% |
| % Held by Institutions | 11.86% |
| Shares Short | 4.32M |
| Short % of Float | 6.87% |
| Short % of Shares Outstanding | 4.17% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -6405.93% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -23.83% |
| Return on Equity (ttm) | -31.33% |
Income Statement
| Revenue (ttm) | 1.33M USD |
| Revenue Per Share (ttm) | 0.01 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -77084000 USD |
| Net Income Avi to Common (ttm) | -29102000 USD |
| Diluted EPS (ttm) | -0.25 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 131.68M USD |
| Total Cash Per Share (mrq) | 1.27 USD |
| Total Debt (mrq) | 50.52M USD |
| Total Debt/Equity (mrq) | 61.69 USD |
| Current Ratio (mrq) | 5.672 |
| Book Value Per Share (mrq) | 0.792 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -70973000 USD |
| Levered Free Cash Flow (ttm) | -42742248 USD |
Profile of Humacyte
| Country | United States |
| State | NC |
| City | Durham |
| Address | 2525 East North Carolina Highway 54 |
| ZIP | 27713 |
| Phone | 919-313-9633 |
| Website | https://www.humacyte.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 164 |
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Q&A For Humacyte Stock
What is a current HUMA stock price?
Humacyte HUMA stock price today per share is 1.35 USD.
How to purchase Humacyte stock?
You can buy HUMA shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Humacyte?
The stock symbol or ticker of Humacyte is HUMA.
Which industry does the Humacyte company belong to?
The Humacyte industry is Biotechnology.
How many shares does Humacyte have in circulation?
The max supply of Humacyte shares is 155.12M.
What is Humacyte Price to Earnings Ratio (PE Ratio)?
Humacyte PE Ratio is now.
What was Humacyte earnings per share over the trailing 12 months (TTM)?
Humacyte EPS is -1.26 USD over the trailing 12 months.
Which sector does the Humacyte company belong to?
The Humacyte sector is Healthcare.
Humacyte HUMA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
| NASDAQ Global Select Market Com NQGS | 7625.89 USD — |
-5.84
|
— — | 7621.56 USD — | 7894.21 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 3904.12 USD — |
-5.49
|
— — | 3901.51 USD — | 4064.61 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}